Toxic shock syndrome secondary prevention: Difference between revisions
No edit summary |
No edit summary |
||
| Line 1: | Line 1: | ||
{{CMG}};{{AE}}{{MIR}} | {{CMG}};{{AE}}{{MIR}} | ||
{{Toxic shock syndrome}} | |||
== Overview: == | == Overview: == | ||
Secondary prevention strategies following toxic shock syndrome (TSS) include [strategy 1], [strategy 2], and [strategy 3] | Secondary prevention strategies following toxic shock syndrome (TSS) include [strategy 1], [strategy 2], and [strategy 3] | ||
| Line 11: | Line 11: | ||
Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin{{WikiDoc Help Menu}} | Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin{{WikiDoc Help Menu}} | ||
Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null <nowiki>[107]</nowiki>] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections. | Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null <nowiki>[107]</nowiki>] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.<ref name="urlSevere Invasive Group A Streptococcal Infections: A Subject Review | AMERICAN ACADEMY OF PEDIATRICS | Pediatrics">{{cite web |url=http://pediatrics.aappublications.org/content/101/1/136.short |title=Severe Invasive Group A Streptococcal Infections: A Subject Review | AMERICAN ACADEMY OF PEDIATRICS | Pediatrics |format= |work= |accessdate=}}</ref> | ||
Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128__NOTOC__ | Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128__NOTOC__ | ||
Revision as of 15:56, 15 May 2017
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1];Associate Editor(s)-in-Chief: Mahshid Mir, M.D. [2]
|
Toxic shock syndrome Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Toxic shock syndrome secondary prevention On the Web |
|
American Roentgen Ray Society Images of Toxic shock syndrome secondary prevention |
|
Risk calculators and risk factors for Toxic shock syndrome secondary prevention |
Overview:
Secondary prevention strategies following toxic shock syndrome (TSS) include [strategy 1], [strategy 2], and [strategy 3]
Secondary Prevention
- First Sentences:
- .
OR
- The primary and secondary prevention strategies for [Disease Name] are the same.
Chemoprophylaxis of household contacts of STSS patients: Household contacts of people with STSS have a higher risk of invasive GAS infection compared to the general population. The Centers for Disease Control and Prevention have not made definite recommendations; some authors have recommended a 10-day course of cephalosporin
Several regimens have been successful in eradicating group A streptococcus from the pharynx of chronic carriers (i.e., rifampin plus intramuscular benzathine penicillin or a 10-day course of a second-generation cephalosporin or clindamycin). [null [107]] However, there are limited data concerning chemoprophylaxis for severe invasive group A streptococcal or staphylococcal infections.[1]
Tanz RR, Poncher JR, Corydon KE, et al. Clindamycin treatment of chronic pharyngeal carriage of group a streptococci. J Pediatr. 1991;119:123-128